Advances in genetics: widening our understanding of prostate cancer [version 1; referees: 2 approved]
Angela C. Pine,
Flavia F. Fioretti,
Greg N. Brooke,
Charlotte L. Bevan
Affiliations
Angela C. Pine
Molecular Oncology, School of Biological Sciences, University of Essex, Colchester, Essex, UK
Flavia F. Fioretti
Androgen Signalling Laboratory, Division of Cancer, Department of Surgery and Cancer, Imperial Centre for Translational & Experimental Medicine, Imperial College London, London, UK
Greg N. Brooke
Molecular Oncology, School of Biological Sciences, University of Essex, Colchester, Essex, UK
Charlotte L. Bevan
Androgen Signalling Laboratory, Division of Cancer, Department of Surgery and Cancer, Imperial Centre for Translational & Experimental Medicine, Imperial College London, London, UK
Prostate cancer is a leading cause of cancer-related death in Western men. Our understanding of the genetic alterations associated with disease predisposition, development, progression, and therapy response is rapidly improving, at least in part, owing to the development of next-generation sequencing technologies. Large advances have been made in our understanding of the genetics of prostate cancer through the application of whole-exome sequencing, and this review summarises recent advances in this field and discusses how exome sequencing could be used clinically to promote personalised medicine for prostate cancer patients.
